Expert Insights On Decentralized Trials

41. Key Learnings To Optimize Clinical Trials During COVID-19 11/4/2022

    Designing and conducting trials during the COVID-19 global pandemic forced clinical teams to be creative, to explore the use of technology, and to design a trial that meets the participants where they are — without compromising outcomes. 

42. Will DCTs Become The Norm? 10/5/2022

    Decentralized clinical trials (DCTs) have been an option for more than a decade, though the pandemic has been the catalyst for change. There is no doubt that DCTs and digitalization are starting to transform clinical research, but will they become the norm?

43. Using RWE In Clinical Trials: Challenges & Opportunities 9/19/2022

    What are real-world data (RWD) and real-world evidence (RWE), and how can we overcome the challenges of integrating them into clinical trials to produce better outcomes?

44. 3 Strategies For Diverse, Large-Scale Clinical Studies 8/18/2022

    Chuanbo Xu of Freenome shares the three strategies that his team used to successfully enroll a diverse patient population across 200 sites for its recent clinical trial.

45. Pharma Companies Are Tapping Digital Health For Improved Patient Outcomes 8/11/2022

    Smarter diagnostic tools and a growing role for remote care will be of huge importance in the new paradigm. The pharma industry, which is already growing its role in delivering hybrid solutions combining therapies with diagnostic and smart solutions and devices, could play a significant role here.

46. How AI/ML Is Helping Clinical Researchers Investigate Alzheimer's 7/28/2022

    Like many cognitive conditions, Alzheimer’s disease can cause changes to a person’s speech and language. Artificial intelligence (AI) and machine learning scientists are working on automating speech assessments to detect the disease earlier and improve understanding of the efficacy of novel treatments. 

47. Your Guide To Harnessing Clinical Trial Sensor Data Better 7/26/2022

    Technological advances in wearables and sensors are speeding the development of digital measures and endpoints. This sensor data is often in native formats unique to each sensor technology and in proprietary clouds owned by the manufacturer. To address this challenge, the Digital Medicine Society released a set of open-access toolkits to support the successful scaling of sensor data to drive better clinical decisions.

48. Designing A Phase 3 Clinical Trial In Rare Dermatology: Lessons Learned 7/15/2022

    Rare dermatologic disease R&D is growing at a much faster rate than other fields in dermatology. Even before the data readout from our Phase 2b study, we began formulating several possible Phase 3 trial designs and asked scientific, operational, and regulatory questions. Here are our lessons learned.

49. Decentralized Clinical Trials: Are We Using The Best Terminology For Patients? 7/12/2022

    There is a need within the clinical trials community for a broad term to describe clinical trials that make use of digital health tech and other methods for better accessibility to participants. However, is a single term as helpful for patients as it is for clinical trial professionals?

50. Diversity In Clinical Research Execution And Participation 6/27/2022

    In this article we compare the 2020 and 2021 result of the WCG Avoca Industry Survey, which explores industry respondents’ views on patient diversity in clinical research participation.